Here, we used HDAC inhibitors and DOT1L inhibitors to study the potential crosstalk between HDACs and DOT1L in the context of CTCL treatment with clinically relevant pan-HDAC inhibitors. Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.